alumis acelyrin - Search News

Acelyrin Adopts Poison Pill

Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to prevent hostile takeovers.

BioSpace · 22h

Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.

MarketWatch · 1d

Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake

Acelyrin said Tang Capital held 8.8% of its outstanding common stock. Tang Capital didn't immediately respond to a request for comment issued through LinkedIn. Poison pills, also called shareholder-rights plans,

Fierce Biotech9d

Acelyrin doubles down on Alumis merger after deciding Concentra's surprise offer 'not superior'

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

How a skin drug trial could help Peninsula biotech pull off key merger

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

BioSpace8d

Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage ...

Acelyrin: Potential Buyout Led By Concentra Biosciences

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results